Release No 6/2010
Affitech A/S announces Annual Report for 2009
Copenhagen and Oslo, April 9th, 2010
Affitech A/S, (Nasdaq OMX: AFFI), the antibody medicines company, today
announced the publication of its Annual Report for 2009. The Report summarises
specific goals that the Company has set itself for undertaking the next phase of
its transformation into an internationally competitive antibody therapeutics
company.
The Annual Report can be downloaded from the Company's website at
www.affitech.com
--------------------------------------------------------------------------------
| For more information please contact: |
--------------------------------------------------------------------------------
| |
| Affitech A/S: |
| |
| Randi Krogsgaard |
| Tel # +45 2320 1001 |
--------------------------------------------------------------------------------
About Affitech A/S
Affitech AS is a publicly traded (NASDAQ OMX Copenhagen) therapeutic antibody
company headquartered in Copenhagen, Denmark with R&D facilities in Oslo,
Norway. The company utilizes a range of proprietary antibody technologies for
the discovery of therapeutic antibodies for application in oncology,
inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is
Affitech A/S's premier technology platform for the isolation of lead antibodies
to cell surface targets. Several of the Company's proprietary drug candidates
were generated by CBAS™. Further information is available at www.affitech.com.
- ends -
